H. Ghatasheh

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation

J. Khader, F. Geara, M. Charafeddine, 2017, Radiation Oncology.

Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.

A. Bazarbachi, O. Shahin, Hadeel Abdelkhaleq, 2022, Clinical lymphoma, myeloma & leukemia.

Evaluation of risk-tailored individualized selection of radiation therapy target volume for Head and Neck Carcinoma of Unknown Primary.

B. O'Sullivan, John J. Kim, E. Hahn, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Primary radiation therapy for advanced‐stage laryngeal cancer: A laryngo‐esophageal dysfunction disease‐free survival

A. Hosni, Ayat Taqash, I. Mohamad, 2022, Laryngoscope investigative otolaryngology.

Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate

A. Hosni, A. Al-Ibraheem, R. Abu-Hijlih, 2023, Journal of clinical medicine.

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation

J. Khader, F. Geara, M. Charafeddine, 2017, Radiation oncology.